CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth -7.7% ·
share flow -0.9% ·
net new positions -8.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 115 | +10 | 52.54M | $4.56B | +17 | −6 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | — |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | — |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | — |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | — | — |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | — | −1 |
| Q2 2024 | 13 | — | 13.78M | $447.82M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 6.51M | -5.8% | $301.24M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.38M | +4.4% | $110.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.38M | +4.4% | $110.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Arrowstreet Capital ✦ | 1.58M | +6.5% | $73.15M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 1.26M | +53.3% | $58.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 788.06K | -17.0% | $36.47M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 788.06K | -17.0% | $36.47M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 356.05K | -9.6% | $16.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 315.95K | +32.2% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 315.95K | +32.2% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 315.95K | +32.2% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Millennium Management ✦ | 239.23K | -20.9% | $11.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 124.73K | -52.0% | $5.77M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 124.73K | -52.0% | $5.77M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 52.93K | +3.5% | $2.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 41.07K | -9.3% | $1.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Wellington Management ✦ | 41.07K | -9.3% | $1.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Wellington Management ✦ | 41.07K | -9.3% | $1.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Wellington Management ✦ | 41.07K | -9.3% | $1.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 18.61K | -25.4% | $861,456 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $656,298 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 347 holders, 79.01M shares, $2.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 4.98K sh · $585,478
Director · 91.17K sh · $10.78M
Director · 7.05K sh · $838,710
Director · 400 sh · $47,855
Officer · 10.00K sh · $1.16M
Director · 3.05K sh · $337,341
Director · 4.67K sh · $520,214
Director · 2.28K sh · $256,706
Officer · 3.66K sh · $419,491
Officer · 11.53K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology